Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sage shakes up leadership, appoints ex AZ and Shire staff

This article was originally published in Scrip

Executive Summary

Biopharmaceutical firm Sage Therapeutics, which develops products to treat CNS disorders and orphan diseases, has appointed Dr Jeffery Jonas chief executive officer. He succeeds Kevin Starr who has been interim CEO since the company's founding in 2011. Prior to joining the Cambridge, Massachusetts-based firm Dr Jonas was president of regenerative medicine at Dublin, Ireland-headquartered biopharmaceutical firm Shire.

You may also be interested in...



How Has COVID-19 Influenced Investment Trends?

Health care funding in the first half of 2020 reached $10.4bn, according to a mid-year report from Silicon Valley Bank, nearly matching 2019’s full-year record. As well as the COVID-19 pandemic though, other global events, such as the US election, could become distractions in the second half of the year.

Fund+ Makes Moves In Europe With Further Growth On The Cards

In this latest installment of VC Playbook, Chris Buyse – former chief financial officer of ThromboGenics – talks to In Vivo about the lessons he has learned from a career as a financial executive in the life sciences and his current venture, Fund+, a Belgian-based investment group focused on innovative companies primarily active in therapeutics R&D.

Snapshot: July Highlights

A selection of articles you might have missed from July 2020, including exclusive interviews with industry leaders and a review of Q2 financing statistics.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel